Lasa Supergenerics Limited
NSE: LASAMarket Closed • NSE
Day range
52 week range
Lasa Supergenerics Limited closed at INR5.16 (+0%) on volume 0x its 20-day average, trading 58.65% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved -63% QoQ
2024-09-20
AGM Announced
Annual General Meeting
2023-09-20
AGM Announced
Annual General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.20x
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Annual General Meeting | Annual General Meeting | — | 20 Sept 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 20 Sept 2023 |
| — | Dividend | ₹0.25 / share | — | 16 Sept 2022 |
| — | Dividend | ₹0.25 / share | — | 15 Sept 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 17 Sept 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 19 Sept 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 17 Sept 2018 |
Traded volume and delivery percentage across the latest 11 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
IndiaHealthcare
Is Lasa Supergenerics Limited Shariah compliant?
Lasa Supergenerics Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (38.15%) exceeds AAOIFI threshold (≤ 33%).
What is Lasa Supergenerics Limited's current valuation relative to peers?
Lasa Supergenerics Limited trades at a P/E of N/A compared to the sector median of 37x, and a Price-to-Book of 0.5x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.20x. Interest coverage is -34.7x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.